Aspen To Buy Part Of GSK's Injectables Business, Plant For $970 Million
This article was originally published in PharmAsia News
Executive Summary
Aspen Pharmacare Holdings has agreed to buy the thrombosis injectable-drugs business of GlaxoSmithKline for $970 million in a deal that also includes a manufacturing plant in France.